4 years ago

Engitix Secures $54 Million Series A Funding to Advance ECM Drug Discovery

  • Engitix, a UK-based biopharmaceutical company focused on drug discovery for fibrosis and solid tumors, has secured $54 million in Series A funding co-led by existing investor Netherton Investments and new investor Dompé

  • This financing will fuel Engitix's internal drug discovery pipeline, expand its ECM discovery platform, and enhance its bioinformatics capabilities

  • Engitix has established collaborations with Dompé, Takeda, and Morphic Therapeutics, leveraging its ECM platform to identify new treatments against various diseases.

      • ProblemHealthcare

      "Fibrosis and solid tumours are difficult to treat, and current treatments are often ineffective or have serious side effects. Existing treatments for liver cancer often fail to penetrate tumours. "

      Solution

      "Engitix is developing a portfolio of internal & partnered drug discovery programs in fibrosis and solid tumours using its pioneering human extracellular matrix (ECM) platform. "

      Covered on